BioNet, a Franco-Thai vaccine biotech group, and PT Bio Farma (Persero), Indonesia's state-owned vaccine manufacturer, have signed a Memorandum of Understanding (MoU) to collaborate on development and regional distribution of a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis).
The partnership combines BioNet's proprietary recombinant pertussis technology and global clinical experience with Bio Farma's large-scale manufacturing and public health reach to address critical immunisation needs in ASEAN (Association of Southeast Asian Nations).
The MoU outlines cooperation in clinical development, regulatory alignment, and market access. Bio Farma leads clinical trials and regulatory submissions in Indonesia, while BioNet handles other ASEAN countries. The collaboration aims to reduce vaccine introduction from 10–15 years to less than five.
The TdaP vaccine combines Bio Farma's Td and BioNet's aP antigens. It targets the ASEAN market with an estimated 10–15 million doses annually, valued at around $200 million.
This partnership aims to strengthen pandemic preparedness, build resilient vaccine supply chains, and improve equitable healthcare access across Southeast Asia.
